The Technical Analyst
Augmedix, Inc. [AUGX]
Exchange: NASDAQ Sector: Healthcare Industry: Health Information Services
Augmedix, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-0.66% $2.99
America/New_York / 19 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 145.73 mill |
| EPS: | -0.440 |
| P/E: | -6.80 |
| Earnings Date: | Mar 25, 2024 |
| SharesOutstanding: | 48.74 mill |
| Avg Daily Volume: | 0.373 mill |
| RATING 2024-04-19 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Strong Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -6.80 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -6.80 | industry: PE -4.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 2.71 - 3.27 ( +/- 9.23%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-15 | Shakil Ian | Sell | 500 | Stock Option (Right to Buy) |
| 2024-04-15 | Shakil Ian | Buy | 500 | Common Stock |
| 2024-04-15 | Shakil Ian | Sell | 500 | Common Stock |
| 2024-04-12 | Shakil Ian | Sell | 19 544 | Stock Option (Right to Buy) |
| 2024-04-12 | Shakil Ian | Buy | 19 544 | Common Stock |
| INSIDER POWER |
|---|
| 0.17 |
| Last 97 transactions |
| Buy: 18 457 414 | Sell: 19 819 523 |
Forecast:
16:00 - $2.99
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $2.99
Forecast 2: 16:00 - $2.99
Forecast 3: 16:00 - $2.99
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $2.99 (-0.66% ) |
| Volume | 0.290 mill |
| Avg. Vol. | 0.373 mill |
| % of Avg. Vol | 77.77 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For AUGX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:34 | sell | $4.29 | N/A | Active |
|---|
AUGX
Augmedix, Inc. provides remote medical documentation solutions and live clinical support services in the United States. Its platform offers Augmedix Live and Augmedix Notes solutions that provide pre-visit documentation, such as pre-charting and digitization of previous records/patient history; during-visit documentation, including medical notes, care gap reminders, HCC reminders, and after-visit summaries; and post-visit documentation consisting of coding, orders, and referrals. The company enables clinicians to access its applications through mobile devices, such as smartphones or Google Glass. It serves health systems and specialty groups. The company was founded in 2013 and is headquartered in San Francisco, California.
Latest Press Releases
2024-04-09 07:00:00 - Press Release
Augmedix Integrates With Andor Health To Revolutionize Ambient Clinical Documentation For Ambulatory Virtual Care
San francisco and orlando, fla., april 09, 2024 (globe newswire) -- in a significant move to streamline healthcare workflows and allow clinicians to focus on patient care, augmedix (nasdaq: augx), a leader in ambient ai medical documentation and data solutions, announced today that it has integrated with andor health , an ai-first cloud-based communication and collaboration platform for virtual care.
2024-04-04 07:00:00 - Press Release
Augmedix And Sada Forge Partnership To Scale Ambient Documentation And Structured Data Products To Health Systems Nationwide
The partnership enables augmedix to accelerate scaling efforts for digital health solutions and integrations that work seamlessly at the point of care the partnership enables augmedix to accelerate scaling efforts for digital health solutions and integrations that work seamlessly at the point of care
2024-03-18 16:01:00 - Press Release
Augmedix Delivers 45% Revenue Growth And Expanded Gross Margins For Fourth Quarter Of 2023
San francisco, march 18, 2024 (globe newswire) -- augmedix (nasdaq: augx), a leader in ambient ai medical documentation and data solutions, today reported financial results for the three and 12 months ended december 31, 2023.
2024-03-12 07:00:00 - Press Release
Augmedix Announces New Positive Data And Enhancements To Its Ambient Ai Product, Augmedix Go
New data shows clinicians save up to 1 hour or more per day using augmedix go new data shows clinicians save up to 1 hour or more per day using augmedix go
2024-03-08 07:00:00 - Press Release
Augmedix To Announce Fourth Quarter And Full Year 2023 Financial Results On March 18, 2024
San francisco, march 08, 2024 (globe newswire) -- augmedix (nasdaq: augx), a healthcare technology company that delivers industry-leading, ambient medical documentation and data solutions, announced today it will release fourth quarter and full year 2023 results after the market closes on monday, march 18, 2024. following the release, management will host a conference call and audio webcast to review results and provide a brief business and outlook update that same day at 1:30 p.m. pt / 4:30 p.m. et.
Latest News
2024-04-19 06:00:00 - InvestorPlace
3 Penny Stocks That Could Make a Big Comeback by the End of Q2
Let's just get something straight off the bat – penny stocks to rebound are risky. They're incredibly treacherous in terms of both short-term downside and longer-term damage to your portfolio.
2024-03-24 00:50:19 - Seeking Alpha
Augmedix: Secular AI Tailwinds, But Still Unattractive Risk-Reward
Augmedix is a company developing an AI-driven medical documentation platform for hospitals and physicians. The company's stock performance has been underwhelming since going public, with a current all-time return of -15%. The company's financials show steady growth but continued losses, and there are concerns about profitability and cash flow generation, making risk-reward unattractive for now.
2024-03-18 23:05:18 - Seeking Alpha
Augmedix, Inc. (AUGX) Q4 2023 Earnings Call Transcript
2024-03-08 07:00:00 - GlobeNewsWire
Augmedix to Announce Fourth Quarter and Full Year 2023 Financial Results on March 18, 2024
SAN FRANCISCO, March 08, 2024 (GLOBE NEWSWIRE) -- Augmedix (Nasdaq: AUGX), a healthcare technology company that delivers industry-leading, ambient medical documentation and data solutions, announced today it will release fourth quarter and full year 2023 results after the market closes on Monday, March 18, 2024. Following the release, management will host a conference call and audio webcast to review results and provide a brief business and outlook update that same day at 1:30 p.m. PT / 4:30 p.m. ET.
2024-01-09 06:21:09 - MarketBeat
Augmedix is an ambient AI healthcare optimization play
Augmedix Inc. NASDAQ: AUGX is an artificial intelligence (AI) powered ambient medical documentation solutions provider in the medical sector. It utilizes generative AI for documenting medical records and transcribing medical notes and conversations, which are seamlessly integrated into the electronic health record (EHR) system used by healthcare systems, insurers, offices, and practices.
2023-11-20 00:35:22 - Seeking Alpha
Buy Augmedix After $25 Million Equity Funding Round
Augmedix dropped in price by 20%+ after announcing a 5.5 million share offering of common stock that was later upsized to 6.25 million shares. Despite concerns of dilution, I rate AUGX a Buy for its revenue growth undergirded by a promising future in the AI marketplace. The Company's product eliminates data entry tasks for doctors, allowing them to focus on delivering care to patients.
2023-11-10 11:16:42 - Zacks Investment Research
How Much Upside is Left in Augmedix, Inc. (AUGX)? Wall Street Analysts Think 36.67%
The consensus price target hints at a 36.7% upside potential for Augmedix, Inc. (AUGX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
2023-11-10 10:33:09 - Zacks Investment Research
Augmedix, Inc. (AUGX) is on the Move, Here's Why the Trend Could be Sustainable
Augmedix, Inc. (AUGX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
2023-11-06 22:51:03 - Seeking Alpha
Augmedix, Inc. (AUGX) Q3 2023 Earnings Call Transcript
2023-10-30 07:00:00 - GlobeNewsWire
Augmedix to Announce Third Quarter 2023 Financial Results and Host Investor Conference Call on November 6, 2023
SAN FRANCISCO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Augmedix (Nasdaq: AUGX), a healthcare technology company that delivers industry-leading, ambient medical documentation and data solutions, announced today it will report financial results for the third quarter ended September 30, 2023, on Monday, November 6, 2023, after the market closes. Management will host a conference call that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.